Peptide 'not that potent' claims: what the data actually says

What's this video probably claiming?

Based on the caption "it's really not that potent" paired with wellness and longevity hashtags, this creator is almost certainly pushing back against hype around one or more research peptides, likely BPC-157, TB-500, GHK-Cu, or a growth hormone secretagogue like ipamorelin or CJC-1295. The framing suggests a contrarian take: that the peptide community is overselling these compounds, or perhaps that a specific peptide's effects are more modest than the biohacking crowd admits. That's actually a reasonable position to stake out. The peptide space on TikTok is saturated with extraordinary claims, so a creator pumping the brakes could be doing legitimate science communication. But "not that potent" is a claim that still needs to be anchored to actual data, not vibes. Without specificity about which peptide, which outcome, and at what dose, the argument is just as hand-wavy as the hype it's critiquing.

What does the science actually show?

The honest answer is that potency varies wildly depending on the peptide in question, the model studied, and the endpoint measured. BPC-157, for instance, has shown meaningful tissue repair effects in rodent models, with Sikiric et al. (2018, Current Pharmaceutical Design) documenting accelerated tendon-to-bone healing at doses around 10 mcg/kg in rats. But there are zero completed randomized controlled trials in humans. GHK-Cu has demonstrated collagen synthesis stimulation in cell culture studies (Pickart et al., 2015, Journal of Aging Science), but translating that to meaningful skin regeneration in a living human at topical concentrations is a different story entirely. Growth hormone secretagogues like ipamorelin do produce measurable GH pulses in humans, but a 2008 study by Raun et al. (European Journal of Endocrinology) showed effects were dose-dependent and context-dependent. "Not potent" is too blunt an instrument to describe this landscape.

Where does the social media noise diverge from clinical reality?

The biggest distortion on both sides of this debate is the leap from animal data to human outcomes. TikTok peptide enthusiasts cite rat studies as if they're phase 3 trials. Critics who call peptides "not that potent" sometimes ignore that some compounds, particularly growth hormone secretagogues, have legitimate mechanistic data in humans. The deeper problem is that most research peptides are studied in isolation under controlled conditions, while users are frequently running multi-peptide stacks with inconsistent dosing, unverified purity, and no clinical oversight. A 2021 analysis by Calof et al. in the Annals of Internal Medicine found that even FDA-approved GH therapy produced modest functional gains in healthy adults, with meaningful side effect profiles. Extrapolating that to unregulated research peptides used without lab monitoring is not a small logical leap. It is a canyon.

What should you actually know?

If this creator is making the specific argument that a particular peptide's effects are overstated, that may well be correct for many compounds and many claimed outcomes. The peptide hype cycle on social media consistently outpaces the published evidence. But "not that potent" can also be a cover for dismissing compounds that do have preliminary mechanistic support, which would be an overcorrection. What matters is which peptide, which outcome, and compared to what baseline. Consumers watching this video should ask whether the creator is citing human data or animal data, whether they're discussing a regulated medical context or gray-market research compounds, and whether potency claims are being made relative to a placebo or to pharmaceutical alternatives. These compounds are not approved by the FDA for the uses being discussed. Access should go through a licensed medical provider who can order appropriate labs and monitor for adverse effects.